Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2012

View Archived Issues

New strategy shows promise to eradicate latent HIV-1

ROCK inhibitor and calcium channel blocker show synergy in phase I trial

New PI3Kalpha and mTOR inhibitors designed in Spain

New antibacterial products presented

Aileron Therapeutics reports new candidate cancer therapies

Prostaglandin E2 derivative shows therapeutic potential in preclinical and clinical studies

New PARP-1 inhibitors synthesized in China

MediVector receives U.S. DOD contract to develop broad-spectrum influenza drug

SK Biopharmaceuticals launches phase II trial of constipation therapeutic

Genmab submits protocol amendment for phase III ofatumumab trial

Pharmaxis provides update on Bronchitol MAA

Medivir to file application for phase I trials of bone disorder candidate

NICE issues recommendation for dabigatran

Wintherix presents new activators of Wnt signaling

Novel somatostatin sst5 receptor antagonists developed

Novel E-NPP 2 inhibitors disclosed

Alcon and Astellas Pharma report new bradykinin receptor agonists

Boehringer Ingelheim Pharma designs new FLAP and leukotriene synthesis inhibitors

Novel hedgehog pathway activators divulged by Fate Therapeutics

FDA grants orphan drug status to verteporfin therapy

Telormedix completes safety portion of TMX-101 study

Galderma completes phase III studies of candidate for facial erythema of rosacea

Health Canada approves diclofenac therapy

TH-302 receives E.U. orphan drug status

Sodium channel blocker enters proof-of-concept trial

FDA proposes adjustment to risk classification of certain tuberculosis tests

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...